Genfit S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNFT research report →
About the company
Genfit S. A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases.
- CEO
- M. Pascal Prigent
- IPO
- 2019
- Employees
- 180
- HQ
- Loos, FR
Price Chart
- Market Cap
- $445.68M
- P/E
- -7.52
- P/S
- 9.60
- P/B
- -27.29
- EV/EBITDA
- -115.23
- Div Yield
- 0.00%
- Gross Margin
- 26.02%
- Op Margin
- -84.25%
- Net Margin
- -127.40%
- ROE
- -596.44%
- ROIC
- -41.41%
- Revenue
- $67.00M · 134.56%
- Net Income
- $1.51M · 105.22%
- EPS
- $0.03 · 105.17%
- Op Income
- $3.28M
- FCF YoY
- 124.55%
- 52W High
- $10.00
- 52W Low
- $2.55
- 50D MA
- $4.12
- 200D MA
- $3.94
- Beta
- 0.87
- Avg Volume
- 10.37K
Get TickerSpark's AI analysis on GNFT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GNFT coverage
Recent articles, reports, and earnings notes.
No research on GNFT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNFT report →Similar companies
Peers in the same neighborhood.